Abstract RF6-07: Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with HER2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): patient-reported outcomes (PROs) from the DESTINY-Breast09 study
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, Goethe University Frankfurt, University Hospital Frankfurt, Chinese PLA General Hospital, Samsung Medical Center, Sungkyunkwan University, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, German Cancer Research Center, National Center for Tumor Diseases, Tokyo Metropolitan Komagome Hospital, İzmir University of Economics, Third Hospital of Nanchang, Yonsei Cancer Hospital, First Hospital of Jilin University, China Medical University, China Medical University Hospital, Ankara Yıldırım Beyazıt University, Ankara Bilkent City Hospital, McGill University Health Centre, IQVIA (France), AstraZeneca (United States), AstraZeneca (Canada), Dana-Farber Cancer Institute
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129756687